ScFv(L19)-interferon-gamma

an engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy; has a fusion between scFv(L19), a human antibody fragment specific to the EDB domain of fibronectin, and a cysteine-free mutant of murine interferon-gamma

Also Known As:

ScFv(L19)-IFN-gamma

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
- Peptides: 82426
  - Peptide Fragments: 373
    - Immunoglobulin Fragments: 976
      - Immunoglobulin Fab Fragments: 769
        Immunoglobulin Variable Region: 208
        Single-Chain Antibodies: 852
        ScFv(L19)-interferon-gamma: 1

Experts

1.	Berndt, Alexander: 1 article (08/2005)
2.	Ebbinghaus, Christina: 1 article (08/2005)
3.	Grabulovski, Dragan: 1 article (08/2005)
4.	Kaspar, Manuela: 1 article (08/2005)
5.	Kosmehl, Hartwig: 1 article (08/2005)
6.	Neri, Dario: 1 article (08/2005)
7.	Ronca, Roberto: 1 article (08/2005)
8.	Zardi, Luciano: 1 article (08/2005)

Related Diseases

1.	Teratocarcinoma 08/20/2005 - "ScFv(L19)-interferon-gamma displayed a strong antitumor effect in both subcutaneous and metastatic murine F9 teratocarcinomas, but was not efficacious as single agent when used to treat C51 and CT26 tumors. "
2.	Neoplasms (Cancer) 08/20/2005 - "ScFv(L19)-interferon-gamma displayed a strong antitumor effect in both subcutaneous and metastatic murine F9 teratocarcinomas, but was not efficacious as single agent when used to treat C51 and CT26 tumors. "